Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention

Samsung Medical Center173 enrolled

Overview

The purpose of this study to determine whether statin pretreatment decrease myocardial infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

173

Conditions

Angioplasty, Transluminal, Percutaneous Coronary

Interventions

atorvastatinDRUG

atorvastatin 80mg/day before primary coronary intervention

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Presence of chest pain for more than 30 minutes but less than 12 hours after symptom onset * ST segment elevation more than 1 mm in two or more contiguous leads or presumably a new onset left bundle branch blockage Exclusion Criteria: * Cardiogenic shock * History of myocardial infarction * Chronic liver disease * Previous or current statin use

Locations (1)

Samsung Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

Myocardial infarct size by SPECT

Time frame: between 5 and 14 days after acute myocardial infarction

Secondary Outcomes

Myocardial infarct size measured by contrast-enhanced MRI

Time frame: within 14 days after acute myocardial infarction

Myocardial blush grade after the procedure

Time frame: immediate after procedure

complete ST resolution

Time frame: at 60 minutes after the procedure

major adverse cardiac events related to left ventricular dysfunction (death, new-onset sustained hypotension or heart failure, and hospital readmission for left ventricular dysfunction)

Time frame: at 6 months after the procedure

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.